Risk factors associated with lymph node metastasis in early-stage distal gastric cancer.

Abstract

This study was designed to explore the risk factors of lymph node metastasis (LNM) in distal gastric cancer with early stage, and to provide reference for the choice of treatment protocols. In this retrospective observational study, 824 early distal gastric cancer (EDGC) cases who treated at our unit from 2010 to 2020 were selected as research objects. Subsequently, univariate and multivariate logistic regression analyses were conducted to investigate the associations between LNM and clinicopathological features. Of these 824 EDGC cases, 140 (17.0%) developed LNM, including 72 N1 stage and 68 N2-3 stage LNM. Multivariate logistic regression analysis identified the tumor diameter ≥1.75cm (odds ratio (OR)=2.361, p<0.001), tumor location (OR=1.552, p=0.046), histological classification (p=0.004), tumor infiltration depth (OR=2.154, p=0.001), and vascular infiltration (OR=4.354, p<0.001) as independent predictors for LNM. Logistic regression analyses based on 756 N0-1 LNM cases identified the smoking history (OR=0.507, p=0.043), tumor diameter ≥1.75cm (OR=2.265, p=0.010), tumor location (OR=1.834, p=0.036), histological classification (p=0.018), tumor infiltration depth (OR=1.939, p=0.034), and vascular infiltration (OR=3.225, p<0.001) as independent predictors for N1 LNM. Moreover, preoperative hypoalbuminemia (OR=7.087, p=0.015), significant preoperative weight loss (OR=2.724, p=0.023), tumor diameter ≥1.75cm (OR=5.484, p=0.001), multiple tumors (OR=9.986, p=0.038), histological classification (p=0.029), and vascular infiltration (OR=33.704, p<0.001) were proved to be associated with LNM for T1a tumors. The tumor diameter, location and infiltration depth, histological classification, and vascular infiltration were expected to be used as predictors of LNM in EDGC, and preoperative hypoalbuminemia, significant weight loss, tumor diameter and number, histological classification, and vascular infiltration were associated with LNM for T1a tumors.